Skip to content
  1. Home
  2. >Test Catalog
  3. >Pharmacogenomics
  4. >Pgx Clopidogrel Test
Back to catalog

Pharmacogenomics (PGx) Clopidogrel CYP2C19 Test

A targeted pharmacogenomic test evaluating CYP2C19 metabolizer status to optimize clopidogrel prescription and dosing, powered by the Helix Exome+® platform.

Turnaround

6-9 days

Turnaround Requery

≤ 5 minutes

Test Description

Clopidogrel is an antiplatelet medication prescribed to patients at increased risk of blood clots, including those who have a history of cardiac events or major cardiac intervention. Clopidogrel prevents the collection of platelets and formation of blood clots in the blood vessels.

This test evaluates a patient’s metabolizer status for CYP2C19, which can aid in appropriate prescription and dosing to reduce risk of side effects and treatment failure with clopidogrel.

View the complete description of this test
Sample Report – Normal Metabolizer
Sample Report – Poor Metabolizer

Have Questions?

Our team is available Monday through Friday, 9am-5pm Pacific Time.

(844) 211 2070clinicalsupport@helix.com

Indications for Testing

Patients in whom clopidogrel therapy is being considered for cardiovascular or neurovascular indications.

Methodology

This test utilizes next-generation sequencing to determine star alleles and metabolizer status for CYP2C19 and is used to determine drug considerations for Clopidogrel.

Technical Specifications

Reportable rangeCYP2C19: *1-*19, *22-*26, *28-*39

Genes Tested

CYP2C19

Showing 1 of 1 genes in this panel

Other Tests to Consider

Test

Malignant Hyperthermia Susceptibility Panel

3

genes

Test

Pharmacogenomics (PGx) APOE Test

1

gene

Test

Pharmacogenomics (PGx) Fluoropyrimidines DPYD Test

1

gene

Test

Pharmacogenomics (PGx) Level A Panel

16

genes

Important Test Information

Turnaround time: Typically 7-10 days (standard), Typically < 5 minutes (requery)

Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit

Shipping Instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.

In order to successfully prevent platelet collection and clot formation, clopidogrel is turned into its active metabolite by CYP2C19. An individual’s CYP2C19 genotype can impact the concentration of active metabolite in the plasma, which may increase risk for treatment failure and adverse cardiac and cerebrovascular events such as heart attack and stroke. Knowing a patient’s CYP2C19 genotype can help determine whether there should be a change in medication to reduce this risk.

All detected variants are evaluated according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Variants are classified based on known, predicted, or possible impact on drug metabolism.